Emergent BioSolutions (EBS) Tops Q2 EPS by 19c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.05 -1.59%
Revenue Growth %: +32.0%
Financial Fact:
Earnings per share - diluted: 0.45
Today's EPS Names:
CCEL, FEIM, PLG, More
Revenue Growth %: +32.0%
Financial Fact:
Earnings per share - diluted: 0.45
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $1.07, $0.19 better than the analyst estimate of $0.88. Revenue for the quarter came in at $220.2 million versus the consensus estimate of $208.57 million.
GUIDANCE:
Emergent BioSolutions sees FY2018 revenue of $715-755 million, versus the consensus of $738.54 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP
- Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
